Genentech

Decision Resources suggests breast cancer market to reach $15B by 2022

Friday, August 23, 2013 11:39 AM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of premium-priced agents will fuel 5% annual growth in the breast cancer market, with sales reaching more than $15 billion in 2022 in the U.S., France, Germany, Italy, Spain, the U.K. and Japan.

More... »

Biogen Idec, Adimab expand collaboration

Friday, July 26, 2013 03:05 PM

Adimab, a provider of an integrated antibody discovery and optimization platform, has expanded its collaboration with Biogen Idec for the discovery of antibody-based therapeutics. 

More... »

Loxo Oncology, Array BioPharma in license, collaboration agreement

Thursday, July 11, 2013 09:10 AM

Loxo Oncology, a biopharmaceutical company established and funded by Aisling Capital, and Array BioPharma have announced a multi-year license and collaboration agreement for an Array-invented preclinical development candidate and related intellectual property. In addition, Loxo and Array will collaborate to discover and develop small molecule drugs for mutually agreed upon novel oncology targets. 

More... »

Immunocore, Genentech collaborate on cancer targets

Tuesday, July 2, 2013 01:17 PM

Immunocore, an Oxford-based biotechnology company developing novel biological drugs known as ImmTACs to treat cancer and viral disease, has entered a research collaboration and licensing agreement with Genentech, a member of the Roche Group, for the discovery and development of multiple novel cancer targets using Immunocore's ImmTAC technology.

More... »

High school junior Natalie Ng wins International BioGENEius Challenge

Friday, April 26, 2013 11:42 AM

Natalie Ng, a junior at Monta Vista High School in Cupertino, Calif., won the International BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research in biotechnology. Ng’s research in breast cancer and biomarkers helped her stand out from the 13 other finalists from across the U.S., Canada and Australia competing for the Challenge's top prize, a $7,500 cash award.

More... »

William Kennedy of Genentech addresses core operational issues in pediatric trials

Wednesday, April 3, 2013 10:47 AM

Increased pressure to conduct trials in children can be daunting when faced with practical, legal and clinical considerations found only in pediatric trials. Successfully implementing regulations and ethical standards into study conduct requires a comprehensive understanding of the unique concerns raised by ethics committees, investigators and parents.

More... »

FDA approves new treatment for late-stage breast cancer

Friday, February 22, 2013 12:41 PM

The FDA has approved Genentech’s Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

More... »

RQx Pharmaceuticals, collaborate on novel drug compounds

Wednesday, February 13, 2013 11:29 AM

RQx Pharmaceuticals, a biopharmaceutical company developing broad-spectrum small molecule antibiotics for serious life-threatening infections, has entered into a drug discovery collaboration with Genentech, a member of the Roche Group, for the discovery and development of novel drug compounds for an undisclosed target.

More... »

Afraxis grants exclusive global license to Genentech

Wednesday, January 30, 2013 09:42 AM

Afraxis, a San Diego-based biotechnology company fully funded by Avalon Ventures, has entered into a global licensing agreement with Genentech, a member of the Roche Group, to develop compounds for an undisclosed novel target.

More... »

Curis licensed IAP inhibitor GDC-0917 from Genentech

Wednesday, November 28, 2012 01:54 PM

Curis, a Lexington, Mass.-based drug development company focused on targeted small molecule drug candidates for cancer treatment, has licensed from San Francisco-based Genentech, a member of the Roche Group, exclusive worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins.

More... »